Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Common Stock and Warrants
-
Shares outstanding
-
55,095,630
-
Total 13F shares
-
18,733,564
-
Share change
-
-1,657,939
-
Total reported value
-
$60,875,021
-
Price per share
-
$3.25
-
Number of holders
-
54
-
Value change
-
-$18,042,573
-
Number of buys
-
31
-
Number of sells
-
31
Institutional Holders of AN2 Therapeutics, Inc. - Common Stock and Warrants (ANTX) as of Q1 2024
As of 31 Mar 2024,
AN2 Therapeutics, Inc. - Common Stock and Warrants (ANTX) was held by
54 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
18,733,564 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., CITADEL ADVISORS LLC, TCG Crossover Management, LLC, Frazier Life Sciences Management, L.P., BVF INC/IL, JANUS HENDERSON GROUP PLC, Avidity Partners Management LP, Octagon Capital Advisors LP, VANGUARD GROUP INC, and ADAGE CAPITAL PARTNERS GP, L.L.C..
This page lists
54
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.